InSilico Medicine (3696.HK) and CMS (867.HK) Announce AI-Focused Drug Development Partnership

Bulletin Express02-10 08:21

InSilico Medicine (“the Company”) and China Medical System Holdings Limited (“CMS”) have entered a strategic partnership to pursue AI-driven drug development projects in the fields of central nervous system and autoimmune diseases, as outlined in a recent announcement.

The agreement integrates the Company’s validated AI platform and drug discovery capabilities with CMS’s extensive R&D resources and disease-area expertise. According to the announcement, InSilico Medicine anticipates R&D funding of several tens of millions of HKD for each of at least two co-development programs.

CMS, with stock codes 867.HK and 8A8.SGX, focuses on global first-in-class and best-in-class innovative pharmaceutical products and holds a strong track record in commercializing specialty therapeutics. InSilico Medicine, listed under the stock code 3696 on the Main Board of the Hong Kong Stock Exchange, is known for harnessing AI and automation technologies to accelerate drug discovery across multiple therapeutic areas.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185193421?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 08:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185193421","market":"hk","top_or_hot":-1,"title":"InSilico Medicine (3696.HK) and CMS (867.HK) Announce AI-Focused Drug Development Partnership","media":"Bulletin Express","content":"<p>InSilico Medicine (“the Company”) and China Medical System Holdings Limited (“CMS”) have entered a strategic partnership to pursue AI-driven drug development projects in the fields of central nervous system and autoimmune diseases, as outlined in a recent announcement.</p>\n<p>The agreement integrates the Company’s validated AI platform and drug discovery capabilities with CMS’s extensive R&D resources and disease-area expertise. According to the announcement, InSilico Medicine anticipates R&D funding of several tens of millions of HKD for each of at least two co-development programs.</p>\n<p>CMS, with stock codes 867.HK and 8A8.SGX, focuses on global first-in-class and best-in-class innovative pharmaceutical products and holds a strong track record in commercializing specialty therapeutics. InSilico Medicine, listed under the stock code 3696 on the Main Board of the Hong Kong Stock Exchange, is known for harnessing AI and automation technologies to accelerate drug discovery across multiple therapeutic areas.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InSilico Medicine (3696.HK) and CMS (867.HK) Announce AI-Focused Drug Development Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInSilico Medicine (3696.HK) and CMS (867.HK) Announce AI-Focused Drug Development Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-10 08:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>InSilico Medicine (“the Company”) and China Medical System Holdings Limited (“CMS”) have entered a strategic partnership to pursue AI-driven drug development projects in the fields of central nervous system and autoimmune diseases, as outlined in a recent announcement.</p>\n<p>The agreement integrates the Company’s validated AI platform and drug discovery capabilities with CMS’s extensive R&D resources and disease-area expertise. According to the announcement, InSilico Medicine anticipates R&D funding of several tens of millions of HKD for each of at least two co-development programs.</p>\n<p>CMS, with stock codes 867.HK and 8A8.SGX, focuses on global first-in-class and best-in-class innovative pharmaceutical products and holds a strong track record in commercializing specialty therapeutics. InSilico Medicine, listed under the stock code 3696 on the Main Board of the Hong Kong Stock Exchange, is known for harnessing AI and automation technologies to accelerate drug discovery across multiple therapeutic areas.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1185193421","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185193421","pubTimestamp":1770682904,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"InSilico Medicine (“the Company”) and China Medical System Holdings Limited (“CMS”) have entered a strategic partnership to pursue AI-driven drug development projects in the fields of central nervous...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"InSilico Medicine(3696.HK)和CMS(867.HK)宣布建立专注于人工智能的药物开发合作伙伴关系","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"InSilico Medicine (“the Company”) and China Medical System Holdings Limited (“CMS”) have entered a strategic partnership to pursue AI-driven drug development projects in the fields of central nervous system and autoimmune diseases, as outlined in a recent announcement.\nThe agreement integrates the Company’s validated AI platform and drug discovery capabilities with CMS’s extensive R&D resources and disease-area expertise. According to the announcement, InSilico Medicine anticipates R&D funding of several tens of millions of HKD for each of at least two co-development programs.\nCMS, with stock codes 867.HK and 8A8.SGX, focuses on global first-in-class and best-in-class innovative pharmaceutical products and holds a strong track record in commercializing specialty therapeutics. InSilico Medicine, listed under the stock code 3696 on the Main Board of the Hong Kong Stock Exchange, is known for harnessing AI and automation technologies to accelerate drug discovery across multiple therapeutic areas.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185193421","isCrawlerRequest":true}